PubMed Health⌕ Search

Biomedical subjects

P S Navashin

Publications and source records attributed to P S Navashin.

At least 19 recordsLinked to original sources
PubMed2001

[Effect of pefloxacin on immune response].

The influence on cellular immune response of different doses of the pefloxacin was studied in vivo as well as in vitro experiments. The pefloxacin in super bactericidal concentrations (2.0 mg/ml and 0.4 mg/ml) possess pronounced supressing effect the T-lymphocyte proliferation in blast transformation reaction. While in concentration 0.08 mg/ml pefloxacin does not show such activity. The pefloxacin in maximal effective concentration (200 mg/kg) suppressed activity in delayed hypersensitivity skin reaction of intact mice towards sheep erythrocytes on 20.3 percent only.

Animals↗
PubMed1999

[Use of pefloxacin in the treatment of patients with purulent wounds of soft tissues].

Pefloxacin was used in the treatment of 25 patients with wound infection in a dose of 400 mg orally twice a day for 10-12 days. As the monotherapy it was applied to 15 patients. 7 patients with clinical signs of non-clostridial anaerobic infection were treated with pefloxacin in combination with intravenous metronidazole. Pefloxacin was highly efficient in 96 per cent of the cases with extensive posttraumatic purulent wounds with and without bone affection, acute purulent wounds of the soft tissue, purulent wounds of the soft tissues in diabetic patients, trophic or decubitus ulcer. 266 clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Proteus mirabilis, Enterobacter spp. and Acinetobacter spp, were tested and 75 to 100 per cent of them was shown to be susceptible to pefloxacin and ciprofloxacin. At the same time the isolates of Pseudomonas aeruginosa and Klebsiella spp. were more susceptible to ciprofloxacin. The pathogen eradication and eradication with superinfection in the cases treated with pefloxacin amounted to 92 per cent. The drug tolerance was good. No clinically significant adverse events were recorded.

Adult↗
PubMed1996

[Effect of lomefloxacin on the synthesis of antibodies to vaccine EV fraction I and hemagglutinins].

Multifactor analysis of the lomefloxacin effect on the primary immune response to T-independent bacterial antigen (vaccine EV fraction 1) and to T-dependent cellular antigen (SRBC) in mice was performed with the use of a wide range of the antibiotic concentrations and the dosage time. It was shown that lomefloxacin in the doses corresponding to the average therapeutic ones used for 3-9 days had no effect on the content of the IgG antibodies, was able to increase the level of the IgM antibodies and insignificantly lowered the concentration of the IgA antibodies.

Animals↗
PubMed1993

[Semisynthetic penicillins: their importance in the current antibiotic therapy of infections. Penicillinase-resistant penicillins with predominantly antistaphylococcal action].

The status of isoxazolylpenicillins in the modern antibiotic therapy of staphylococcal infections is discussed from various viewpoints: the role and distribution of methicillin resistant staphylococci (MRSA), the methicillin tolerance, the clinical pharmacology and pharmacokinetics, the preferable administration routes and regimens depending on the disease severity and renal function, the prophylaxis of purulent infections, the indications to the combined therapy and possible side effects. It is indicated that one of the conditions providing the efficacy of penicillinase stable antistaphylococcal penicillins is the absolute knowledge of their properties and the joint efforts of the clinicians and bacteriologists in providing a rapid change of the drug after the detection of MRSA or methicillin tolerant staphylococci. This excludes any discredit of the drugs which are useful in the modern antistaphylococcal therapy.

Humans↗
PubMed1991

[Study of the immunotropic activity of aminoglycoside antibiotics].

The action of some aminoglycoside antibiotics on the immune system was studied on both intact mice and the animals with immune deficiency caused by administration of cyclophosphamide. The following tests were used: local hemolysis (the Herne test), lymphocyte transformation (LT), delayed hypersensitivity to sheep red blood cells and the local graft versus host reaction (GVHR). Amikacin was shown to have no significant action on the activity of lymphocytes in the intact mice and stimulated both cellular (LT and GVHR) and humoral (the Herne test) immunity in the animals with lowered immunological reactivity. Sisomicin had no significant action on the immune system of the animals. Gentamicin suppressed the immune response only in the intact mice. Kanamycin and streptomycin induced inhibition of humoral and cellular immunity in both the intact mice and animals with immune deficiency. On the basis of the results it was concluded that gentamicin, amikacin and sisomicin may be used in the treatment of diseases developing in the presence of immune deficiency whereas streptomycin and kanamycin should be recommended when inhibition of the immunity is needed.

Adjuvants, Immunologic↗
PubMed1990

[Antibacterial treatment of infectious-toxic shock].

The studies enabled one to identify six leading clinicophysiological syndromes developing in patients with infective toxic shock (ITS). They include signs of purulent inflammatory processes, organ disorders and systems disturbances. Despite the clinical picture polymorphism, ITS has a clearly defined stage-by-stage process which makes it possible to determine hyperdynamic and hypodynamic phases of the pathological process within each stage. An absolute condition for antimicrobial drugs includes the following: drainage of the purulent inflammatory focus, arresting of pathogen discharge into the blood flow, recovery of host impaired functions and their maintenance. It was shown that a wrong choice of the drugs and antibacterial therapy regimens resulted in a 2-fold increase in fatal cases with ITS. Disorders in systemic and organ blood flows and microcirculation and coagulation disturbances played a particular role in decreasing antibacterial therapy efficacy. Further ways for optimizing antibacterial therapy are mainly connected with availability of efficient antibacterial drugs for practitioners and introduction of microbiological and pharmacokinetic monitoring of antibacterial therapy providing conditions for their rational and safe use.

Anti-Bacterial Agents↗
PubMed1989

[Role of microbiological control in the choice of antibacterial therapy of respiratory infection in surgical patients during the postoperative period].

The paper presents data on observation of 416 surgical patients subjected to investigation of sputum and washings from the tracheobronchial tree for estimating the role of clinico-microbiological study of respiratory tract excretions from surgical patients in choice of adequate therapy. On the basis of the obtained data and results of clinical observations a scheme of clinico-microbiological criteria was developed which would be of help for clinicians and microbiologists in difficult differential diagnosis of colonization and infection. The scheme will provide clinical microbiologists with possibility of correct interpretation of the results of studying respiratory tract excretions and presenting information containing preliminary positive or negative indications as to the presence of infection and recommendations for continuation or discontinuation of further clinico-microbiological investigations.

Anti-Infective Agents↗